Nevertheless, while many HLA class I ligands have been identified for various KIRs, several have remained more elusive, particularly those for activating KIRs.
KIR3DS1 was the first KIR to be associated with the outcome of a viral infection; that is, delayed progression of disease in patients infected with human immunodeficiency virus type 1 (HIV-1) who have certain HLA-B alleles 6 . Since then, it has been extensively linked to other viral infections [6] [7] [8] [9] , autoimmune disorders 10 , the development and clearance of several cancers [11] [12] [13] and transplantation outcomes 14, 15 and therefore has become one of the most studied KIRs. KIR3DS1 is an activating receptor that stimulates cytotoxicity and interferon-γ (IFNγ) production in NK cells 16 . It is encoded by the KIR3DL1-KIR3DS1 locus, a unique KIR locus because it encodes functionally divergent products 1 . Remarkably, while they share >95% homology in their extracellular domain, KIR3DS1 and its inhibitory counterpart KIR3DL1 have different ligand-binding profiles. KIR3DL1 has conclusively been shown to bind HLA-A and HLA-B proteins with a Bw4 motif (HLA-Bw4), with variable sensitivity to carboxy-terminal residues of HLA-Bw4-bound peptides and to residues at position 80 of HLA class I 17 . However, attempts to identify a KIR3DS1 ligand have repeatedly failed 18, 19 , save for a single study demonstrating peptide-dependent binding of KIR3DS1 to HLA-B*57:01 in vitro 20 . Disease-association studies have found both KIR3DL1 and KIR3DS1 to be influential in disease outcome, including the pathogenesis of disease due to 1 0 6 8 VOLUME 17 NUMBER 9 SEPTEMBER 2016 nature immunology A r t i c l e s HIV-1 infection, when present together with HLA-Bw4 (refs. 6, 21) , but direct KIR3DS1-HLA-Bw4 interactions are a major point of controversy. Indeed, some studies have reported independence of KIR3DS1 from HLA-Bw4 (refs. 22,23) . Furthermore, even in studies linking KIR3DS1 and HLA-Bw4, the vast majority of subjects with KIR3DS1 also had KIR3DL1, which imposes a confounding variable, since HLA-Bw4 is a well-documented ligand for KIR3DL1. Of note, while KIR3DL1 exhibits substantial sequence polymorphisms that have been shown to alter surface expression 24 and ligand binding 25, 26 , KIR3DS1 is remarkably conserved and almost completely monomorphic. This is despite the fact that KIR3DS1 arose in the human genome >3 million years ago along with various alleles of KIR3DL1 and is present in almost all human populations worldwide 1 .
The goal of the present study was to identify ligands of KIR3DS1 and thus show the mechanistic basis for its influence in various human diseases. To this end, we employed soluble-receptor-binding assays and cell-based functional assays to comprehensively screen HLA class I proteins in two biologically relevant conformation states: as HLA class I complexes, which are folded heavy chains bound to β 2 -microglobulin (β 2 m) and peptide; and as HLA class I 'open conformers' (OCs), which are HLA class I heavy chains not bound to β 2 m or peptide 27 . We identified HLA-F OCs as high-affinity ligands of KIR3DS1 and also ligands of lower affinity for the inhibitory receptors KIR3DL1 and KIR3DL2. Using reporter cell lines, primary KIR3DS1 + NK cells and primary CD4 + T cells, we also demonstrated that this interaction was of functional relevance, which provides an explanation for the widespread influence of KIR3DS1 in human disease.
RESULTS
HLA class I screen showing KIR3DS1 binding to HLA-F We aimed to systematically assess the binding of KIR3DS1 to various allotypes of HLA class I in two conformational states: as HLA class I complexes, and as HLA class I OCs. To accomplish this, we assessed the binding of soluble KIR3DS1-Fc (a soluble, dimerized protein chimera composed of the extracellular domain of KIR3DS1 fused to the crystallizable fragment (Fc) region of human IgG1) and other KIR-Fc fusion constructs to beads coated individually with each of 97 allotypes of classical HLA class I proteins (i.e., HLA-A, HLA-B and HLA-C) that were either left untreated or acid pulsed. Acid pulsing is a wellestablished method of stripping away β 2 m and HLA-class-I-bound peptides to rapidly generate HLA class I OCs. KIR3DS1-Fc did not bind appreciably to any of the classical HLA class I allotypes tested, either as complexes (untreated) or as OCs (acid pulsed) ( Fig. 1a) . However, KIR3DL1-Fc bound 'preferentially' to HLA-Bw4 complexes, and KIR2DL3-Fc and KIR2DS4-Fc bound to HLA-C complexes ( Fig. 1a and Supplementary Fig. 1a ), as expected. KIR3DL2-Fc did not show any 'preferential' binding to specific HLA class I proteins. Of note, HLA class I complexes on these beads presented a diverse repertoire of peptides derived from the human cell line in which in the HLA class I proteins were produced, which precluded the possibility of any analysis of peptide specificity. Thus, KIR3DS1 did not bind to classical HLA class I complexes (presenting a diverse 'immunopeptidome') or HLA class I OCs.
Because non-classical HLA class I proteins (i.e., HLA-E, HLA-F and HLA-G) were not included in the original panel of beads coated with HLA class I, we produced these separately. Streptavidin beads were coated with biotinylated monomers of HLA-E, HLA-F or HLA-G refolded around β 2 m and peptide (no peptide for HLA-F, given that it does not present peptide 28 ). To confirm that the HLA class I proteins were in complex conformation after being loading onto beads, we assessed by flow cytometry the binding of an antibody to all HLA class I complexes (anti-pan-HLA class I complex) to the beads coated with HLA class I before and after acid pulsing; this antibody can recognize all HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G proteins, but only when they are bound to β 2 m. As expected, all acid-pulsed beads did not bind anti-pan-HLA class I complex due to stripping of β 2 m (Supplementary Fig. 1c ). However, we found that for untreated beads, while HLA-E and HLA-G readily bound anti-pan-HLA class I complex, HLA-F did not (Supplementary Fig. 1c ). We assessed β 2 m content on the untreated beads coated with HLA class I by staining with antibody to β 2 m (anti-β 2 m) and found that beads coated with HLA-F had ~60% less β 2 m content than that of beads coated with HLA-E or HLA-G ( Supplementary Fig. 1c ). This indicated that unlike other HLA class I proteins, HLA-F readily dissociated from β 2 m and spontaneously formed HLA-F OCs on artificial surfaces, consistent with its unique property of being stable as an OC 29 .
By testing the binding of KIR-Fc constructs to beads coated with non-classical HLA class I, we found that KIR3DS1-Fc strongly bound to beads coated with HLA-F; this was independent of acid treatment, consistent with the finding that both untreated beads and acid-pulsed beads contained HLA-F OCs (Fig. 1b,c) . KIR3DL1-Fc and KIR3DL2-Fc were similarly able to bind beads coated with HLA-F (either acid pulsed or untreated); however, KIR2DL3-Fc and KIR2DS4-Fc did not bind to any beads coated with non-classical HLA class I ( Fig. 1b and Supplementary Fig. 1b ). Consequently, we concluded from this assay that KIR3DS1, along with the functional divergent KIR3DL1 and the phylogenetically related KIR3DL2 (ref. 1), bound to HLA-F OCs.
Surface plasmon resonance of KIR3DS1-HLA-F binding To confirm our findings, we performed surface plasmon resonance to quantitatively assess the affinity of various KIRs for HLA-F OCs. KIR3DS1 had the highest affinity for HLA-F OCs of the KIRs assessed (with a dissociation constant (K D ) = 25 ± 1 nM (mean ± s.e.m.)), followed by KIR3DL2 (K D = 118 ± 1 nM) and KIR3DL1 (K D = 157 ± 2 nM), while KIR2DS4 and KIR2DL3-Fc did not exhibit any binding, even at the highest concentration tested ( Fig. 2a and Table 1 ). The kinetics data showed that the affinity of KIR3DS1 for HLA-F OCs was driven mainly by a smaller dissociation rate (k d = 7.0 × 10 −4 ± 0.3 × 10 −4 s −1 (mean ± s.e.m.)) than that of KIR3DL1 (k d = (6.91 × 10 −3 ± 0.09 × 10 −3 s −1 ) or KIR3DL2 (k d = 5.08 × 10 −3 ± 0.04 × 10 −3 s −1 ), reflective of a greater stability of the interaction once formed. Together these data demonstrated that all 'lineage II KIRs' (i.e., KIR3DL1, KIR3DS1 and KIR3DL2) were able to bind HLA-F OCs, although with varying affinities and in a manner opposite to that involving binding to classical HLA class I molecules, to which inhibitory KIRs normally bind with much greater affinity.
Activation of KIR3DS1 hi ζ Jurkat reporter cells by HLA-F
To determine whether cell-expressed KIR3DS1 could bind to and be activated by target cells expressing HLA-F OCs, we developed a reporter cell assay using Jurkat cells, which are a human T lymphocytic cell line that does not express HLA-F, HLA-G or HLA-Bw4. We performed CRISPR-Cas9-mediated knockout of β 2 m in Jurkat cells to eliminate surface expression of HLA class I ( Supplementary  Fig. 2a ) and to prevent potential self-activation. Jurkat cells were then stably transduced with chimeric receptors containing the extracellular and transmembrane domain of the KIR of interest and the cytoplasmic domain of CD3ζ (called 'KIRζ' here) ( Supplementary Fig. 2b) . For KIR3DS1, we used the transmembrane domain of KIR3DL1 instead to ensure cell-surface expression in the absence of its adaptor DAP12, as has been shown before 30 (called 'KIR3DS1 hi ζ' here).
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We confirmed surface expression of KIRζ on Jurkat cells by staining with antibodies to the relevant KIRs ( Supplementary Fig. 2c ). Expression of the activation marker CD69 served as a reporter-cell output; its utility was validated by antibody-mediated crosslinking of KIRζ ( Supplementary Fig. 2d ).
Initially we assessed the ability of KIRζ + Jurkat cells to bind to and be triggered by cell-sized beads coated with HLA class I; this assay showed that KIR3DS1 hi ζ + Jurkat cells avidly bound to and were potently triggered by beads coated with HLA-F, as were KIR3DL2ζ + Jurkat cells and KIR3DL1ζ + Jurkat cells, although to a much lesser extent ( Supplementary Fig. 2e ). As expected, no binding or triggering by beads coated with HLA-F was observed for KIR2DL3ζ + or untransduced Jurkat reporter cells ( Supplementary Fig. 2e ). Next we assessed the reporter activity of KIRζ + Jurkat cells incubated with cell lines left untreated or acid pulsed to generate HLA class I OCs at the cell surface (confirmed by staining with antibody to HLA class I OCs; Supplementary Fig. 2f ). 721.221 cells are a highly mutated, Epstein-Barr virus-transformed human B-cell line that does not express HLA-A, HLA-B, HLA-C or HLA-G but does express HLA-E (at low levels) and HLA-F. Because of their intrinsic deficiency in HLA class I, 721.221 cells are commonly used as target cells in NKcell assays. Analysis of the reporter activity of KIRζ + Jurkat cells incubated with 721.221 cells revealed that acid-pulsed 721.221 cells potently stimulated KIR3DS1 hi ζ + Jurkat cells (Fig. 2b) , a result that occurred independently of other HLA class I allotypes expressed (Supplementary Fig. 3a ). KIR3DL2ζ + Jurkat cells and KIR3DL1ζ + Jurkat cells were also triggered by acid-pulsed 721.221 cells, but less potently than the triggering of KIR3DS1 hi ζ + Jurkat cells ( Fig. 2b) , in line with the binding data. KIR2DL3ζ + Jurkat cells were not triggered by acid-pulsed 721.221 cells (Fig. 2b) . These data indicated that KIR3DS1 (as well as KIR3DL2 and, to a lesser extent, KIR3DL1) bound to HLA-F OCs independently of classical HLA class I.
In assessing the reporter activity of KIRζ + Jurkat cells incubated with other cell lines, we found that acid-pulsed Epstein-Barr virustransformed B cell lines (BCLs) derived from HLA-typed patients also stimulated KIR3DS1 hi ζ + Jurkat cells, while other cell lines that do not express HLA-F (i.e., Jurkat cells, EL-4 mouse T lymphoblastoid cells, K562 human chronic myelogenous leukemia cells, and THP-1 human acute monocytic leukemia cells) did not ( Fig. 2b and Supplementary  Fig. 3b ). In a separate experiment in which surface expression of KIRζ was accounted for, triggering of KIRζ + Jurkat cells by acid-pulsed BCLs revealed the greatest reporter activity for KIR3DS1 hi ζ, followed by KIR3DL2ζ and then KIR3DL1ζ ( Fig. 2c) , which correlated with the affinities determined by surface plasmon resonance ( Table 1) . These data showed that among 'lineage II KIRs' (i.e., KIR3DL1, KIR3DS1 and KIR3DL2), KIR3DS1 exhibited the most potent functional signaling capacity after engagement of HLA-F OCs on target cells.
To further confirm the interaction between KIR3DS1 and HLA-F OCs, we performed antibody-blockade experiments. Of note, we did not have a specific blocking antibody to HLA-F OCs at our disposal. Instead, we used two antibodies to HLA class I OC: HC10, which binds HLA-B, HLA-C and HLA-E OCs but has been shown to indirectly 'downregulate' HLA-F OCs from the cell surface of target cells via endocytosis 29 ; and HCA2, which binds HLA-A and HLA-G OCs but, as we determined, exhibits reactivity to HLA-F OCs (Supplementary Fig. 1c) . Accordingly, the reporter activity of npg A r t i c l e s KIR3DS1 hi ζ + Jurkat cells induced by acid-pulsed BCLs was blocked by an antibody that recognizes both KIR3DS1 and KIR3DL1 (anti-KIR3DS1-KIR3DL1) and by each antibody to HLA class I OCs but not by an antibody that recognizes only KIR3DL1 (anti-KIR3DL1) or anti-pan-HLA class I complex (Fig. 2d) . In addition, the addition of soluble KIR3DS1-Fc to block ligands on target cells also reduced the reporter activity of KIR3DS1 hi ζ + Jurkat cells induced by acid-pulsed BCLs (Supplementary Fig. 3c ). These antibody-blockade experiments confirmed the interaction of KIR3DS1 with HLA-F OCs. On the other hand, the reporter activity of KIR3DL1ζ + Jurka cells triggered by BCLs expressing HLA-Bw4 was blocked by both anti-KIR3DL1 and anti-pan-HLA class I complex but not by either antibody to HLA class I OCs (Supplementary Fig. 3d ). This confirmed the well-documented interaction between KIR3DL1 and HLA-Bw4 complexes. Of note, the weak reporter activity of KIR3DL1ζ + Jurkat cells stimulated by acidpulsed BCLs without HLA-Bw4 was blocked by both anti-KIR3DL1 and anti-HLA class I OC but not by anti-pan-HLA class I complex (Fig. 2d) . This further showed an interaction between KIR3DL1 and HLA-F OCs that was functionally much weaker than that of KIR3DS1, a remarkable finding given their high homology.
HLA-F triggers polyfunctional responses in KIR3DS1 + NK cells
To assess the functional effect of the binding of HLA-F OC to KIR3DS1 in primary human NK cells, we generated KIR3DS1 + and KIR3DS1 − NK-cell lines (NKCLs) via limiting-dilution cloning from peripheralblood NK cells from healthy donors. We confirmed that the NKCLs were CD56 + KIR3DL1 − LILRB1 − , to ensure proper functionality, and that they had variable expression of KIR2D receptors ( Supplementary  Fig. 4a ). NKCLs were seeded into individual well plates coated with human immunoglobulin G (IgG) (for crosslinking of the NK-cell receptor CD16 (FcγRIII)), anti-KIR3DS1-KIR3DL1(for crosslinking of KIR3DS1), or monomers of HLA-E, HLA-F or HLA-G. To assess the responses of NKCLs to plate-bound ligands, we measured the exocytosis of cytotoxic granules (i.e. degranulation), as determined by surface expression of the lysosome-associated marker CD107a, and production of the antiviral cytokines IFN-γ, TNF and MIP-1β by intracellular staining. Plate-bound HLA-F triggered strong and significant degranulation in KIR3DS1 + NKCLs but not in KIR3DS1 − NKCLs ( Fig. 3a and Supplementary Fig. 4c ). The magnitude of this response was comparable to that achieved after crosslinking of KIR3DS1 or CD16 and was significantly diminished by the addition of soluble anti-KIR3DS1-KIR3DL1 (Fig. 3a) . Plate-bound HLA-E and HLA-G produced a weak response by some but not all NKCLs, and this activation was not blocked by soluble anti-KIR3DS1-KIR3DL1 (Fig. 3a) . The observed effects were not due to intrinsic differences in response capacity, as all NKCLs (except for one that was CD16 − ) were similarly triggered by crosslinking of CD16 (Fig. 3a) . In addition, HLA-F induced production of IFN-γ, TNF and MIP-1β in KIR3DS1 + NKCLs (but not in KIR3DS1 − NKCLs), and these responses were blocked by soluble anti-KIR3DS1-KIR3DL1 ( Fig. 3b  and Supplementary Fig. 4c) . Notably, KIR3DS1 + NKCLs had an intrinsic ability to produce antiviral cytokines superior to that of KIR3DS1 − NKCLs when they encountered the same stimuli (Supplementary Fig. 4d ). Together these data demonstrated that HLA-F was able to trigger a potent activating signal via KIR3DS1 that resulted in a polyfunctional response by primary NK cells.
Induction of KIR3DS1 ligand expression by CD4 + T-cell activation
HLA-F can be expressed on the surface of activated lymphocytes 31 .
To study the expression of KIR3DS1 ligands in a biologically relevant context, we assessed HLA-F expression and the binding of KIR3DS1-Fc to primary resting CD4 + T cells and CD4 + T cells stimulated with interleukin 2 (IL-2) and beads coated with antibody to the invariant signaling protein CD3 (anti-CD3) and antibody to the costimulatory receptor CD28 (anti-CD28). We used an immunoblot-compatible antibody to HLA-F (specificity validation, Supplementary Fig. 5a ) to assess protein expression, and resistance to digestion with endoglycosidase H (Endo H) served as a measure of cell-surface expression. Endo H is a glycosidase that removes immature N-glycans from glycoproteins that have not undergone Golgi processing; thus, glycoproteins shuttled to the cell surface through the Golgi are rendered resistant to Endo H (i.e., no band shift during electrophoresis of proteins through a gel). Our results showed that while unstimulated CD4 + T cells did not have any detectable HLA-F protein, stimulated CD4 + T cells expressed HLA-F protein in a predominantly Endo H-resistant form (Fig. 4a) , indicative of cell-surface expression; similar results were obtained with different stimulation conditions (48 h of treatment with phorbol 12-myristate 13-acetate (12.5 ng/ml) and ionomycin (0.335 µM); data not shown).
To determine if upregulation of the expression of HLA-F protein in activated CD4 + T cells was due to increased transcription, we assessed HLA-F mRNA via flow-cytometry-based fluorescence in situ hybridization. We used HLA-F mRNA-specific probes after testing their sensitivity and specificity in HLA-F + and HLA-F − cell lines (Supplementary Fig. 5b) . Activation of CD4 + T cells increased the abundance of HLA-F mRNA (Fig. 4b) , which indicated transcriptional induction of the gene encoding HLA-F in CD4 + T cells after activation. Furthermore, there was significant binding of KIR3DS1-Fc to stimulated CD4 + T cells but not to unstimulated CD4 + T cells ( Fig. 4c and  Fig. 4d) . These results were consistent for patients with and without HLA-Bw4, which demonstrated that KIR3DS1 ligands were expressed on activated CD4 + T cells regardless of their HLA class I genotype.
HIV-1 infection alters KIR3DS1 ligand expression
To assess the influence of HIV-1 infection on the expression of KIR3DS1 ligands in CD4 + T cells, we assessed HLA-F mRNA and binding of KIR3DS1-Fc in activated CD4 + T cells that were uninfected or infected with HIV-1 strain NL4-3. HLA-F mRNA expression was upregulated in HIV-1-infected activated CD4 + T cells relative to its expression uninfected activated CD4 + T cells (Fig. 5c) , which indicated that HIV-1 infection further stimulated the transcription of HLA-F mRNA. In contrast, binding of KIR3DS1-Fc diminished significantly after HIV-1 infection (Fig. 5a,b) . The decrease in KIR3DS1-Fc binding was observed in 'early' infected cells (defined as p24 lo CD4 + and positive for HLA class I and tetherin) but was more pronounced in 'late' infected cells (defined as p24 hi CD4 lo with low 1 0 7 2 VOLUME 17 NUMBER 9 SEPTEMBER 2016 nature immunology A r t i c l e s expression of HLA class I and tetherin) ( Fig. 5a,b) , which indicated an as-yet-unknown mechanism by which HIV-1 might reduce the expression of KIR3DS1 ligands. This might have been due to direct downregulation of the expression of HLA-F protein by HIV-1; however, due to the absence of an available antibody to HLA-F suitable for flow cytometry, it was not possible to directly quantify surface expression of HLA-F on HIV-1-infected cells.
Suppression of HIV-1 replication by KIR3DS1 + NK cells
To evaluate the antiviral capacity of KIR3DS1 + NK cells, we cultured HIV-1-infected autologous CD4 + T cells for 7 d with KIR3DS1 + or KIR3DS1 − NKCLs derived from a KIR3DS1 +/+ donor (NK-cellreceptor phenotypes, Supplementary Fig. 4b ). We used intracellular staining of the HIV-1 core antigen p24 to quantify the frequency of infected cells. Only KIR3DS1 + NKCLs were effective at suppressing HIV-1 replication in autologous CD4 + T cells, as indicated by significantly fewer p24 + CD4 + T cells in the presence of KIR3DS1 + NK cells (5.48% ± 1.60% (mean ± s.d.)) than in the presence of KIR3DS1 − NKCLs (16.9% ± 2.32%; P < 0.01) or no NK cells (16.0% ± 2.62%) ( Fig. 5d,e) . Thus, KIR3DS1 + NK cells showed an antiviral activity against HIV-1-infected autologous CD4 + T cells superior to that of KIR3DS1 − NK cells, as reported before 32 , and HIV-1-mediated downregulation of the expression of KIR3DS1 ligands on infected cells was not sufficient to enable complete evasion of the immune system.
DISCUSSION
Expression of the activating NK-cell receptor KIR3DS1 is correlated with the outcome of various human diseases; however, the precise nature of a ligand that could account for such broad biological effects has remained unknown, although this has been studied extensively. Here we identified HLA-F OCs as ligands for KIR3DS1 and showed that HLA-F OCs triggered polyfunctional responses in primary human NK cells through KIR3DS1. We further demonstrated that KIR3DS1 ligands, in particular HLA-F, were expressed on the surface of activated CD4 + T cells. However, after infection of activated CD4 + T cells with HIV-1, surface expression of KIR3DS1 ligands was downregulated, yet this did not abolish efficient suppression of viral replication by co-cultured KIR3DS1 + NK cells in vitro.
Our findings provide insight into the protective effect of KIR3DS1 during HIV-1 infection and an explanation for the widespread influence of KIR3DS1 in human disease. Differential binding of KIR3DS1 and the other 'lineage II KIRs' 1 to HLA-F is remarkable from a structural homology perspective and is shared with other related receptors. The leukocyte immunoglobulinlike receptor (LILR) family is another group of HLA class I-binding receptors encoded by genes found near the KIR locus in the leukocyte receptor complex 33 . The LILR family has inhibitory members (i.e., LILRBs) that bind HLA class I complexes, as well as activating members (i.e., LILRAs) that bind HLA class I OCs 27,34 , a property our data would suggest is partially shared with KIRs; two members in particular, LILRB1 and LILRB2, exhibit robust binding to HLA-F 35 . In our study, we found that all 'lineage II KIRs' bound HLA-F OCs, with KIR3DS1 exhibiting the highest affinity of binding to HLA-F OCs and the most potent functional signaling capacity after engagement of HLA-F OCs on target cells. KIR3DL2, which we found also bound to HLA-F OCs, as has been shown before 36 , shares ~86% extracellulardomain sequence identity with KIR3DS1, which readily explains the differences in their binding affinity. However, it is remarkable that despite the >97% identity in the extracellular domain sequences of KIR3DS1 and KIR3DL1, KIR3DS1 bound to HLA-F OCs with much higher affinity than did KIR3DL1, while KIR3DL1 (but not KIR3DS1) bound to HLA-Bw4 ligands with high affinity. Structural studies indicate that the few amino-acid differences between KIR3DS1 and KIR3DL1 are at sites critical for HLA class I binding 37 , which might explain the differences in ligand-binding profiles. From an evolutionary standpoint, these differences in the binding of KIR3DL1 to various HLA-Bw4 allotypes and KIR3DS1 to HLA-F (which is highly conserved and has one predominant HLA-F*01:01 allotype at a frequency >95% (ref. 38)) provide an explanation for the considerable polymorphicity of KIR3DL1 and the relative monomorphicity of KIR3DS1.
This newly identified KIR3DS1-HLA-F axis has many similarities with the well-known stress-induced NKG2D-MIC-A (or MIC-B) axis, even in the context of HIV-1 infection. Although it is less well studied, HLA-F bears unique and distinguishing characteristics that separates it from all other HLA class I molecules. According to a study investigating the genesis and architectural evolution of the major histocompatibility complex locus, HLA-F acted as the ancestral progenitor of today's genes encoding HLA class I molecules and MICA and MICB 39 . HLA-F has retained features that are similar to those of MIC-A and MIC-B, including being peptide devoid and being able to refold in vitro with and without β 2 m, which is indicative of its unique ability to be stable as an OC 29 and is in line with our data presented here. In agreement with published studies 31, 40 , our data showed expression of HLA-F OCs on the surface of activated CD4 + T cells. Also, although it was assessed only partially in our study of BCLs, several studies have indicated that cancers of various tissue origins aberrantly express HLA-F 40, 41 . Additionally, infection of CD4 + T cells with HIV-1 increased transcription of the gene encoding HLA-F but reduced the expression of KIR3DS1 ligands, particularly in 'lateinfected' cells, which might suggest the use of a strategy for evading the immune system. This is potentially mediated by downregulation of HLA-F expression by HIV-1 accessory proteins, similar to what has been described for the regulation of HLA-A and HLA-B [42] [43] [44] and NKG2D ligands 45 by the HIV-1 accessory protein Nef, as well as for the regulation of HLA-G by the HIV-1 accessory protein Vpu 46 . Our findings are therefore reminiscent of the upregulation of expression of the NKG2D ligands MIC-A and MIC-B on the surface of activated T cells, virus-infected cells and transformed cells, which, in the context of HIV-1, is downregulated by the actions of Nef 45 .
HLA-F expression is tightly regulated 47 , with restricted tissue expression 35, 40 , and is located predominantly in the endoplasmic reticulum. This indicates that HLA-F expression might serve as a marker for specific kinds of cell stress, such as endoplasmic reticulum stress. Similar to the phenomenon seen for MIC-A 48, 49 , HLA-F can be a target for humoral immune responses, as shown in a study that reported the presence of antibodies to HLA-F in the serum of patients with cancer but not in that of healthy control subjects 41 . Collectively, these studies emphasize a critical role for HLA-F in human diseases, and our data demonstrating that KIR3DS1 recognized HLA-F OCs identifies a previously unknown mechanism for the surveillance of stressed cells by the innate immune system.
While the binding of KIR3DS1 to HLA-F explains its widespread influence on human diseases, it does not fully explain the well-known association of KIR3DS1 with the control of disease caused by HIV-1, which has been reported only for HLA-Bw4 + patients. Several studies have confirmed, however, that in the context of HIV-1 infection, the presence of KIR3DS1 and KIR3DL1 together is associated with diminished viremia, delayed progression to AIDS and better in vitro viral inhibition by NK cells in patients expressing HLA-B with a Bw4 motif and an isoleucine at position 80 (refs. 7,50) . The protective effect of this compound genotype can be explained by independent but functionally synergistic effects of KIR3DS1-HLA-F and KIR3DL1-HLA-Bw4 interactions, the latter of which has independently been linked to delayed progression of disease caused by HIV-1 (ref. 21) . Of note, a single study has demonstrated binding of KIR3DS1 to HLA-B*57:01 presenting two HIV-1 peptides that were identified in an exhaustive screen of various viral peptide databases 20 . However, it is not clear whether this interaction has real functional consequences or represents an exceptional case in which a peptide can overcome amino-acid substitutions in KIR3DS1 that normally result in abrogation of HLA-Bw4 binding. Indeed, KIR3DS1 has been linked to many other human diseases without association to HLA-Bw4 (refs. 9,12,15) , which suggests that KIR3DS1 exerts disease-modulatory effects independently of HLA-Bw4. KIR3DS1-HLA-F interactions between NK cells and pathologically altered target cells would incur the well-known innate function of NK cells to recognize and eliminate target cells expressing 'stressed self ' ligands. That hypotheses was supported by our in vitro co-culture assay, which showed that KIR3DS1 + NK cells were more effective at suppressing HIV-1 replication in autologous CD4 + T cells than were KIR3DS1 − NK cells. In addition, our data showed that KIR3DS1-HLA-F interactions elicited NK-cell production of antiviral and pro-inflammatory cytokines such as IFN-γ, TNF, and MIP-1β, which would have pleiotropic effects on immune responses. Furthermore, KIR3DS1-HLA-F interactions between NK cells and activated CD4 + T cells would also suggest a means of NK-cell-mediated regulation of the adaptive immune system. That hypothesis is supported by published studies of mouse models of infection with lymphocytic choriomeningitis virus showing that NK cells regulate adaptive immunity by killing activated CD4 + T cells, which results in diminished immunopathology 5 . Thus, the ability of KIR3DS1 to bind to HLA-F OCs expressed on activated immune cells and/or infected target cells provides a mechanistic link between KIR3DS1 and the progression of disease caused by HIV-1 and would also have relevance for the pathogenesis of other infectious diseases, autoimmune disorders and tumor immunosurveillance.
In conclusion, the interaction between KIR3DS1 and HLA-F OCs described here has identified a previously unknown mechanism by which NK cells recognize target cells. Further studies will be needed to determine the role of KIR3DS1-HLA-F interactions in NKcell-mediated regulation of immunity and/or elimination of pathologically altered target cells. Each of the clinical conditions KIR3DS1 has been linked to, including autoimmune disorders 10 , transplantation outcomes 14, 15 , the development and clearance of cancer [11] [12] [13] and viral infection [6] [7] [8] [9] , offers a variety of prospects for therapeutically exploiting the interactions of KIR3DS1 with HLA-F.
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